Drugs / Custodiol HTK
last change Apr 2016 re-read 3 minutes ago

Custodiol HTK

Developed for
coronary artery disorder · heart valve disorder · myocardial ischemia
Investigated by
Essential Pharmaceuticals, LLC · Marc Sakwa, MD

Trials 1

201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01681095 Aug 2012 → Aug 2014 coronary artery disorder, heart valve disorder, myocardial ischemia Marc Sakwa, MD Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Custodiol HTK ClinicalTrials.gov intervention name — accepted as the source's own label NCT01681095 ↗
Route Other “was infused into the ascending aorta” NCT01681095 ↗